title: GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.
authors.affiliation: From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.). ken.margulies@uphs.upenn.edu thomas.cappola@uphs.upenn.edu.
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Margulies
authors.affiliation: From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.).
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Anstrom
authors.affiliation: From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.).
authors.forename: Adrian F
authors.initials: AF
authors.lastname: Hernandez
authors.affiliation: From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.).
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Redfield
authors.affiliation: From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.).
authors.forename: Monica R
authors.initials: MR
authors.lastname: Shah
authors.affiliation: From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.).
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald
authors.affiliation: From the Perelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M., T.P.C.); Duke Clinical Research Institute, Durham, NC (K.J.A., A.F.H.); Mayo Clinic, Rochester, MN (M.M.R.); Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (M.R.S.); and Harvard Medical School, Boston, MA (E.B.). ken.margulies@uphs.upenn.edu thomas.cappola@uphs.upenn.edu.
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Cappola
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists* / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use*; D013318:Stroke Volume / Q000187:drug effects*; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D052216:Glucagon-Like Peptide 1
keywords: clinical trial; glucagon-like peptide-1; heart failure; insulin resistance